Lisata Therapeutics, Inc. (LSTA) · Nov 19, 2026 · Rights change

Lisata reverse split sets 1-for-15 ratio ahead of conversion vote

1-for-15 reverse split — Shares fall from ~10.8M to ~0.7M; effective November 23

Lisata’s reverse split makes the maximum authorized consolidation effective November 23, setting the share-count framework ahead of its pending preferred-stock conversion vote.

Lisata is rebuilding its capital structure around the recently acquired Marea pipeline, not reporting new clinical progress. The company is now a clinical-stage pharmaceutical business whose lead asset, MAR001, is in Phase 2b development for severe hypertriglyceridemia, alongside MAR002 and certepetide.

The reverse split turns an already-approved option into a specific action, but adds little business information. Stockholders had already authorized a ratio anywhere from 1-for-5 to 1-for-15 on November 9; the board chose the maximum consolidation, effective November 23. 〔0〕 That makes the exact ratio new, but the event itself was largely anticipated.

This changes the share count, not the underlying ownership or operating story. Every 15 shares become one, taking issued and outstanding stock from approximately 10.8 million shares to approximately 0.7 million, while ownership percentages remain essentially unchanged. 〔1〕 The move is therefore mechanical: it does not fund the pipeline, improve trial odds, or alter the economics of the Marea assets by itself.

Its importance is mainly as preparation for the unresolved post-Marea capitalization. Lisata’s recent filings indicate that conversion of its Series C preferred stock remains subject to stockholder approval and Nasdaq-related conditions, with the conversion vote scheduled to reconvene on November 30. The reverse split sets the share-count framework before that decision, but this filing does not resolve the conversion, dilution, or financing questions.

Bottom line: This is a limited, partly anticipated capital-structure action. It keeps Lisata moving through its recapitalization process, but does not advance the clinical or commercial case; the November 30 preferred-stock vote matters more.

What to watch next

Preferred-stock conversion vote, November 30

Original filing on SEC EDGAR

More Lisata Therapeutics, Inc. news

Lisata reverse split sets 1-for-15 ratio ahead of conversion vote | LSTA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.